Study Purpose: This study looks at how safe and tolerable a new medicine called lumateperone is when given as a shot in the muscle to people with schizophrenia or schizoaffective disorder. It also checks how the body processes the medicine, known as pharmacokinetics (PK).
Who Can Join: Men and women ages 18 to 55 who have been stable with their schizophrenia or schizoaffective disorder for at least 3 months. Participants should not have any other major mental health issues and should be in good health according to the study doctors.
Study Details: This is a Phase 1b, open-label study, meaning both the doctors and patients know what treatment is being given. Participants will receive a single shot of lumateperone. The study will keep track of how they are doing to make sure the medicine is safe and works well.
- Time Involved: One-time shot, plus follow-up visits for safety checks.
- Compensation: Participants may receive payment for their time and travel.
- Risks: Possible side effects include pain at injection site, feeling tired, or other symptoms. Safety checks will be conducted.